225 related articles for article (PubMed ID: 21239226)
1. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.
Silver N; Allen RP; Senerth J; Earley CJ
Sleep Med; 2011 May; 12(5):440-4. PubMed ID: 21239226
[TBL] [Abstract][Full Text] [Related]
2. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.
Allen RP; Ondo WG; Ball E; Calloway MO; Manjunath R; Higbie RL; Lee MR; Nisbet PA
Sleep Med; 2011 May; 12(5):431-9. PubMed ID: 21493132
[TBL] [Abstract][Full Text] [Related]
3. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of restless legs syndrome with dopamine agonists.
Ondo W; Romanyshyn J; Vuong KD; Lai D
Arch Neurol; 2004 Sep; 61(9):1393-7. PubMed ID: 15364685
[TBL] [Abstract][Full Text] [Related]
5. Methadone for refractory restless legs syndrome.
Ondo WG
Mov Disord; 2005 Mar; 20(3):345-8. PubMed ID: 15580610
[TBL] [Abstract][Full Text] [Related]
6. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
[TBL] [Abstract][Full Text] [Related]
7. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of painful sensory symptoms in restless legs syndrome: experience from two clinical trials.
Hornyak M; Sohr M; Busse M;
Sleep Med; 2011 Feb; 12(2):186-9. PubMed ID: 21256799
[TBL] [Abstract][Full Text] [Related]
9. Restless legs syndrome: clinical presentation diagnosis and treatment.
Wijemanne S; Jankovic J
Sleep Med; 2015 Jun; 16(6):678-90. PubMed ID: 25979181
[TBL] [Abstract][Full Text] [Related]
10. Latest guidelines and advances for treatment of restless legs syndrome.
Earley CJ
J Clin Psychiatry; 2014 Apr; 75(4):e08. PubMed ID: 24813409
[TBL] [Abstract][Full Text] [Related]
11. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
[TBL] [Abstract][Full Text] [Related]
12. Long-term use of pramipexole in the management of restless legs syndrome.
Lipford MC; Silber MH
Sleep Med; 2012 Dec; 13(10):1280-5. PubMed ID: 23036265
[TBL] [Abstract][Full Text] [Related]
13. Recurrence of cluster headache with pramipexole.
Ossemann M
Acta Neurol Belg; 2010 Sep; 110(3):279-80. PubMed ID: 21114140
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with pramipexole in the treatment of restless legs syndrome.
Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.
Montagna P; Hornyak M; Ulfberg J; Hong SB; Koester J; Crespi G; Albrecht S
Sleep Med; 2011 Jan; 12(1):34-40. PubMed ID: 20965780
[TBL] [Abstract][Full Text] [Related]
16. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model.
Luo F; Li C; Ondo WG; Xu P; Xie W; Le W
Sleep Med; 2011 Jan; 12(1):41-6. PubMed ID: 21044864
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute.
García-Borreguero D; Allen RP; Kohnen R; Högl B; Trenkwalder C; Oertel W; Hening WA; Paulus W; Rye D; Walters A; Winkelmann J; Earley CJ;
Sleep Med; 2007 Aug; 8(5):520-30. PubMed ID: 17544323
[TBL] [Abstract][Full Text] [Related]
18. Compulsive habits in restless legs syndrome patients under dopaminergic treatment.
Pourcher E; Rémillard S; Cohen H
J Neurol Sci; 2010 Mar; 290(1-2):52-6. PubMed ID: 19969309
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Utility of Opioids for Restless Legs Syndrome.
Mackie SE; Winkelman JW
Drugs; 2017 Aug; 77(12):1337-1344. PubMed ID: 28616844
[TBL] [Abstract][Full Text] [Related]
20. Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome.
Worthington A; Thomas L
Eur J Echocardiogr; 2008 Nov; 9(6):828-30. PubMed ID: 18579494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
